Analysis of clinical trials shows pipeline for therapeutics is small; 99.6 percent of drug attempts fail
Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer’s disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. The paper, “Alzheimer’s Disease Drug Development Pipeline: Few Candidates, Frequent Failures,” was published today in the journal Alzheimer’s Research & Therapy.
A comprehensive look at all clinical trials underway shows:
- There are relatively few drugs in development for Alzheimer’s disease.
- The failure rate for AD drug development is 99.6 percent for the decade 2002-2012.
- The number of drugs has been declining since 2009.
“Our goal was to examine historical trends to help understand why Alzheimer’s disease treatment development efforts so often fail,” said Jeffrey L. Cummings, M.D., ScD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. “With an estimated 44 million people living worldwide with the condition, the study shows that the Alzheimer’s disease drug development ecosystem needs more support given the magnitude of the problem.”
Read more . . .
The Latest on: Alzheimer’s drug development
[google_news title=”” keyword=”Alzheimer’s drug development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s drug development
- Scientists find hormone that could stop Alzheimer’son May 17, 2024 at 4:01 pm
Dundee University scientists ‘excited’ by drug that could prevent and reverse brain damage caused by the condition ...
- Ionis, Biogen Down on Ending Development of ALS Drugon May 17, 2024 at 1:04 pm
Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced their decision to terminate the development of their i ...
- Voyager doses first patient with anti-tau antibody in Alzheimer’s trialon May 17, 2024 at 12:29 pm
The Phase Ia trial will evaluate the safety and efficacy of Voyager’s tau-targeting humanised IgG4 monoclonal antibody VY-TAU01.
- New Study in Nature Medicine Shows Novel Neuroprotective Drug Candidate Meets Primary Endpoint in Patients with Mild to Moderate Alzheimer's Diseaseon May 17, 2024 at 11:32 am
A study published today in Nature Medicine found that a novel neuroprotective drug candidate, LM11A-31, was safe and well-tolerated following dosing for 26 weeks in patients with mild to moderate ...
- Research Offers New Ideas for Treating Alzheimer’son May 17, 2024 at 8:33 am
It remains a matter of scientific debate whether the beta amyloid buildup is the cause of Alzheimer’s or a feature of it. It’s time to look at “out of the clump” fresh approaches.
- Pharma company raises millions to fund Alzheimer's, cardiovascular drug researchon May 16, 2024 at 10:25 am
The drug is being tested as a potential treatment for Alzheimer's disease and hypoplastic left heart syndrome, a pediatric disease that affects normal blood flow through the heart.
- More than 20,000 volunteers join effort to accelerate dementia drug developmenton May 14, 2024 at 11:57 pm
More than 20,000 volunteers have been recruited to a resource aimed at speeding up the development of much-needed dementia drugs. The cohort will enable scientists in universities and industry to ...
- Takeda Commits $100M for Chance to Bring Immunotherapy to Alzheimer’s Diseaseon May 13, 2024 at 2:51 pm
Takeda Pharmaceutical has secured an option on an Alzheimer’s disease immunotherapy from AC Immune that is on track to report its first Phase 2 data later this quarter. Exercising the option would ...
- Takeda nabs option to license Alzheimer’s immunotherapies from AC Immuneon May 13, 2024 at 9:45 am
The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.” ...
- Takeda nabs AC Immune Alzheimer’s therapy for $100M upfronton May 13, 2024 at 9:09 am
Takeda is adding ACI-24.060 to its pipeline. The Alzheimer’s therapy targets amyloid beta buildup in the brain and is currently being investigated in a Phase 1b/2 trial.
via Bing News